Skip to main content

empasiprubart

empasiprubart: 2 clinical trials tracked.

empasiprubart evidence translation

What we can confirm

2 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about empasiprubart, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 0 study sponsors

Study sponsors

No additional listed-company sponsor is linked.

Clinical Trial Registry Records (2)

A Phase 3, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Efficacy and Safety of Intravenous Empasiprubart Versus Intravenous Immunoglobulin in Adults With Chronic Inflammatory Demyelinating Polyneuropathy

NCT06920004Registry updated 2026-09-24·Phase 3
Recruiting

Primary endpoint: Reduction of ≥1 point compared with baseline in aINCAT score at week 24

InterventionalRandomizedquadruple218 targetStarted 2025-08Completion 2030-0950 sites · Argentina, Australia, Austria, Brazil…argenx

A Phase 3, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Efficacy and Safety of Empasiprubart Versus Intravenous Immunoglobulin in Adults With Multifocal Motor Neuropathy

NCT06742190Registry updated 2026-09-22·Phase 3
Active, not recruiting

Primary endpoint: Change from baseline in grip strength (4-week average) in the most affected hand at week 24

InterventionalRandomizedquadruple154 enrolledStarted 2024-12Completion 2029-1250 sites · Australia, Austria, Belgium, Brazil…argenx